Close Menu

NEW YORK (GenomeWeb News) – Helicos BioSciences said in a filing with the US Securities and Exchange Commission Friday that it has approximately $200,000 in cash and cash equivalents remaining and will require "significant additional capital" to continue operations.

The company's CEO, Ivan Trifunovich, also has taken on the position of president and CEO of Fremont, Calif.-based WaferGen Biosystems but will remain Helicos' president and chief executive on a part-time basis, "as he has done during the past six months," according to the firm.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
21
Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.